| Package | us.nlm.vsac |
| Type | ValueSet |
| Id | 2.16.840.1.113762.1.4.1196.495 |
| FHIR Version | R4 |
| Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.495/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495 |
| Version | 20210909 |
| Status | active |
| Date | 2021-09-09T01:01:05-04:00 |
| Name | ICSLABALAMAPreparations |
| Title | ICS LABA LAMA Preparations |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: This valueset contains oral inhaled corticosteroid preparations in combination with a long-acting beta agonist and a long-acting muscarinic antagonist that may be used for maintenance controller therapy in adult asthmatics. As of Sept 2020, the oral inhalant combination of fluticasone furoate + umeclidinium + vilanterol is indicated for the maintenance treatment of asthma in patients aged 18 years and older.),(Data Element Scope: FHIR MedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: Includes fluticasone/umeclidinium/vilanterol oral inhalation preparations),(Exclusion Criteria: none) |
No resources found
| CodeSystem | |
| rxnorm | RxNorm |
No narrative content found in resource
FHIR